Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT‐ACS Trial

Abstract

BackgroundThe Effects of the P‐Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non‐ST‐Segment Elevation Myocardial Infarction (SELECT‐ACS) trial suggested beneficial effects of inclacumab, a monoclonal antibody directed against P‐selectin, on periprocedural myocardial damage. This study evaluated the effect of inclacumab on myocardial damage according to varying time intervals between study drug infusion and percutaneous coronary intervention (PCI).Methods and ResultsPatients (n=544) enrolled in the SELECT‐ACS trial and randomized to receive 1 infusion of placebo or inclacumab (5 or 20 mg/kg, administered between 1 and 24 hours before PCI) were divided according to the time interval between study drug infusion and PCI. The primary end point was the change in troponin I from baseline at 16 and 24 hours after PCI. In patients receiving inclacumab 20 mg/kg with a short (less than median) time interval between infusion and PCI, placebo‐adjusted geometric mean percent changes in troponin I, creatine kinase–myocardial band, and peak troponin I at 24 hours were −45.6% (P=0.005), −30.7% (P=0.01), and −37.3% (P=0.02), respectively. No significant changes were observed in patients with a long (greater than median) time interval between infusion and PCI. Placebo‐adjusted geometric mean percent changes in troponin I and creatine kinase–myocardial band were −43.5% (P=0.02) and −26.0% (P=0.07), respectively, when inclacumab 20 mg/kg was administered between 1 and 3 hours before PCI, whereas the drug had no effect with longer intervals.ConclusionsInclacumab 20 mg/kg significantly reduces myocardial damage after PCI in patients with non–ST‐segment elevation myocardial infarction, and benefits are larger when the infusion is administered <3 hours before PCI.Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT01327183.

Liraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway

“…Despite advances in the treatment of coronary artery disease, acute myocardial infarction (AMI) remains the leading cause of human mortality worldwide ( 1 ). AMI is characterized by a sudden reduction in blood and oxygen supply to the heart, irreversible muscle damage and cardiomyocyte death, resulting in the formation of an infarct zone containing nonfunctional myocytes, which are remodeled into scar tissue ( 2 ). The limited ability of the damaged heart to regenerate the damaged myocardium leads to the progression of cardiac decompensation and heart failure ( 3 ).…”

Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions

“…Table 1 summarizes several trials of agents that modulate a specific pathway, often downstream from the initial insult. Most clinical trials targeting specific downstream targets, such as oxidation of LDL [126], secretory and lipoproteinassociated phospholipase A2 (sPLA2 and LpPLA2) [127e129], Pselectin [130,131] and even the IL-1b inhibitor anakinra [132] failed to meet their primary end-points with respect to a decrease in cardiovascular disease or selected surrogate end-point.…”

Endothelial cells, neutrophils and platelets: getting to the bottom of an inflammatory triangle

“…It is evident that the interplay between neutrophil, endothelial and platelet activation cannot be reduced to a single initiator of thrombosis, vessel stenosis or tissue fibrosis. Therefore, while blocking neutrophil-vessel interactions has shown therapeutic promise in reducing neutrophil-mediated vessel damage [81,[88][89][90][91][92], pro-inflammatory neutrophil-platelet interactions are a compelling target for emerging therapeutics [93].…”